CatalYm raises €50M to boost solid tumors trial
CatalYm has announced the close of a €50 million ($49 million) series C financing round. …
CatalYm has announced the close of a €50 million ($49 million) series C financing round. …
This week, we have three interviews on the theme of antimicrobial resistance (AMR), to mark…
FundaMental Pharma GmbH, a preclinical neuroscience company spun out of Heidelberg University in Germany, has…
InfanDx AG, a privately held diagnostics company focusing on the development and commercialization of novel…
How can a drug be delivered exactly where it is needed, while limiting the risk…
Researchers in Japan and Germany say a radiopharmaceutical treatment targeting a prostate-specific membrane antigen effectively…
Patients with nasopharyngeal cancer are often treated with drugs that activate their immune system against…
German company, Centogene N.V., today (November 4) announced its launch of Biodata Network, a portfolio…
The Hamburg-based Evotec spinout Breakpoint Therapeutics is working on cancer treatments that block the ability…
Tetris Pharma Ltd, a subsidiary of biopharma company Arecor Therapeutics plc, has launched Ogluo (glucagon…
A molecular patient database for Sjögren’s syndrome (SjS) and systemic lupus erythematosus (SLE) is to…
An international collaboration marking the start of commercial production of lutetium-177 was celebrated in Munich…